{"success":true,"data":{"pressRelease":{"id":"166342","rtpr_id":"nGNX6wHhjH-20261012","ticker":"GERN","exchange":"NASDAQ","all_tickers":["GERN"],"title":"Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia","author":"Globe Newswire","published_at":"2026-10-12T12:03:31.091Z","article_body":"Presentations feature real-world experience and clinical evidence in\nlower-risk MDS, underscoring growing global scientific engagement with\nimetelstat \n\nFOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation\n(Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more\nmeaningful moments for people living with blood cancer, today announced two\noral presentations and one poster presentation highlighting imetelstat in\npatients with lower-risk myelodysplastic syndromes (LR-MDS) at the 88(th)\nAnnual Meeting of the Japanese Society of Hematology and the 2026 Annual\nMeeting of the German, Austrian and Swiss Societies for Hematology and Medical\nOncology. These presentations will feature real-world evidence and findings\nfrom the Phase 3 IMerge trial.\n\n“We’re encouraged by the growing interest in imetelstat across the global\nhematology community, supported by both the clinical evidence from IMerge and\nan expanding body of real-world evidence in lower-risk MDS,” said Joseph E.\nEid, M.D., Executive Vice President, Research and Development and Chief\nMedical Officer of Geron. “These presentations provide an important\nopportunity to share evidence relevant to patient populations across regions\nand engage with clinicians as we evaluate opportunities to bring\nimetelstat’s potential to more people living with LR-MDS around the\nworld.”\n\nKey takeaways from the presentations:\n\n88(th) Annual Meeting of the Japanese Society of Hematology 2026\n* Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic\nSyndromes: Insights From United States Claims Data (Eid, et al. Oral\n#O1-11C-4) * The retrospective study used closed medical and pharmacy claims\nwith linked enrollment and laboratory data from the Komodo Health database and\nincluded adults with MDS who initiated imetelstat between June 2024 and August\n2025, representing the first 14 months after the launch of imetelstat in the\nU.S.\n* In this real-world U.S. cohort (N=58), with a mean age of 75 years at\ndiagnosis, most patients (71%) initiated imetelstat in the third line or\nlater, with considerable anemia and a mean Charleson Comorbidity Index of 2.6\nat the time of initiation.\n* Despite substantial comorbidity burden, most patients remained on therapy\nthrough the early months when cytopenias typically emerge (~67% at 6 months;\nKaplan-Meier [KM] estimate).\n \n* Durable Clinical Outcomes With Imetelstat in Korean Patients With LR-MDS\n(Eid, et al. Poster #P3-12-5) * This post-hoc study explores characteristics\nof two Korean patients with LR-MDS who had over one year of red blood cell\ntransfusion independence (RBC-TI) with imetelstat, and explores the\nrelationship between cytopenias and treatment outcomes with imetelstat in 13\nKorean patients from the Phase 2/3 and heart rate-corrected QT interval (QTc)\nsubstudy of IMerge.\n* Both patients who achieved long-term response with imetelstat experienced\ngrade 3/4 neutropenia and grade 3/4 thrombocytopenia events early during\ntreatment; most resolved to grade ≤2 in <4 weeks, consistent with the\nbroader IMerge data.\n* Durable efficacy and manageable safety with imetelstat was exhibited in\nKorean patients across a range of patient and disease characteristics (sex, RS\nstatus, baseline erythropoietin [EPO], and baseline platelet levels).\n* In the 13 Korean patients, early cytopenias with imetelstat were associated\nwith better clinical outcomes, as previously reported in IMerge.\n2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology\nand Medical Oncology\n* Telomerase Inhibition With Imetelstat in Patients With Lower-Risk\nMyelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and\nClinical Outcomes (Brauer, et al. Oral #V755) * This presentation integrates\nkey evidence from the Phase 2/3 and QTc substudy of IMerge to support clinical\npractice, reporting on molecular changes, cytopenias and clinical outcomes\nwith imetelstat in LR-MDS, including emerging evidence suggesting treatment\nmay potentially alter the underlying biology of the disease.\n* Transient cytopenias observed early in treatment may be the result of an\non-target effect of imetelstat and may be predictive of a better therapeutic\nresponse.\n* Certain patients with LR-MDS and transfusion-dependent (TD) anemia who\nexperience sustained RBC-TI (≥8-week, ≥24-week, or ≥1-year) with\nimetelstat may experience improved health-related outcomes, including fatigue,\nQUALMS Total, QUALMS-P, and QUALMS-E scores.\nThe presentations are available on the “Publications & Presentations\n(https://www.globenewswire.com/Tracker?data=Lp8NcNEVJXMkQMAvpwFxQiHbltSpZTzTsv6hhG4M03qAmByzmI8FaMjJ53S9TqSS6y4z8bm9-KonRlfJYMJkIKEXQkq5_kBIwsb3kzjaD_MTF0exUYuTuHurO2MHWAt3-We0jYIse_Sl1fnYr_x2Fw==)”\npage of the Geron website.\n\nAbout RYTELO (imetelstat)\nRYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the\nU.S. for the treatment of adult patients with lower-risk myelodysplastic\nsyndromes (LR-MDS) with transfusion-dependent anemia requiring four or more\nred blood cell units over eight weeks who have not responded to or have lost\nresponse to or are ineligible for erythropoiesis-stimulating agents (ESAs). It\nis indicated to be administered as an intravenous infusion over two hours\nevery four weeks.\n\nIn addition, RYTELO is approved in the European Union as a monotherapy for the\ntreatment of adult patients with transfusion-dependent anemia due to very low,\nlow or intermediate risk myelodysplastic syndromes without an isolated\ndeletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory\nresponse to or are ineligible for erythropoietin-based therapy.\n\nRYTELO is a first-in-class treatment that works by inhibiting telomerase\nenzymatic activity. Telomeres are protective caps at the end of chromosomes\nthat naturally shorten each time a cell divides. In LR-MDS, abnormal bone\nmarrow cells often express the enzyme telomerase, which rebuilds those\ntelomeres, allowing for uncontrolled cell division. Developed and exclusively\nowned by Geron, RYTELO is the first and only telomerase inhibitor approved by\nthe U.S. Food and Drug Administration and the European Commission.\n\nPlease see RYTELO (imetelstat) full Prescribing Information, including\nMedication Guide, available at\nhttps://pi.geron.com/products/US/pi/rytelo_pi.pdf.\n\nAbout Geron\nGeron is a hematology-focused biopharmaceutical company pursuing more\nmeaningful moments for people living with blood cancer. Because patients\ncannot wait, we approach our work with urgency, bringing together deep\nexpertise in telomerase biology with patient perspectives and insights from\nclinical research and real-world care. Our medicine, RYTELO(®) (imetelstat),\nis approved in the United States and European Union for certain patients with\nlower-risk myelodysplastic syndromes (LR-MDS). We are building on our\nfoundation in telomerase inhibition by studying imetelstat in myelofibrosis,\nincluding a pivotal Phase 3 clinical trial in patients with JAK-inhibitor\nrelapsed/refractory disease, as well as other hematologic malignancies. Geron\nis a commercial-stage company with offices in Parsippany, New Jersey and\nFoster City, California. To learn more, visit www.geron.com or follow us on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=TSGgR31HMBNF7dY52wvOkKAlQsiuBLX1wiNJ4nA94QhfTFtIjCVqKc-MIOcZjgqFh-2A8Cz-UWNlFl9QfDH52jhmh8s3S7RSkD8F_TmZtco=).\n\nUse of Forward-Looking Statements\n\nExcept for the historical information contained herein, this press release\ncontains forward-looking statements made pursuant to the “safe harbor”\nprovisions of the Private Securities Litigation Reform Act of 1995. These\nforward-looking statements include, without limitation, those regarding: (i)\nthe potential clinical significance of data presented from the IMerge trial\nand real-world evidence analyses; (ii) the potential relationship between\ntreatment-emergent cytopenias and clinical outcomes; (iii) the potential for\nimetelstat to affect the underlying biology of lower-risk MDS; (iv) Geron’s\nplans and efforts to expand awareness and understanding of imetelstat through\nscientific engagement; (v) Geron’s plans to pursue opportunities to bring\nimetelstat to patients outside the United States; (vi) the future development\nof imetelstat in lower-risk myelodysplastic syndromes, myelofibrosis and other\nhematologic malignancies; and (vii) other statements that are not historical\nfacts. These forward-looking statements involve risks and uncertainties that\ncan cause actual results to differ materially from those in such\nforward-looking statements. These risks and uncertainties, include, without\nlimitation, risks and uncertainties related to: (a) whether data analyses and\nobservations from clinical trials and real-world experience are predictive of\nfuture clinical outcomes; (b) whether imetelstat demonstrates\ndisease-modifying activity or other benefits in patients; (c) whether\ntreatment-emergent cytopenias are predictive of clinical outcomes or reflect\non-target biological activity; (d) whether future clinical trial results,\nanalyses and observations are consistent with prior findings; (e) whether\nregulatory authorities permit the continued development of imetelstat on a\ntimely basis, or at all; (f) whether Geron is successful in commercializing\nRYTELO outside of the United States; (g) whether there are failures or delays\nin manufacturing or supplying sufficient quantities of RYTELO or clinical\ntrial materials; and (h) risks and uncertainties relating to the development,\nregulatory review, and commercialization and market acceptance of imetelstat.\nAdditional information regarding these risks and uncertainties and additional\nrisks, uncertainties and factors that could cause actual results to differ\nmaterially from those in the forward-looking statements are contained in\nGeron’s filings and periodic reports filed with the Securities and Exchange\nCommission under the heading “Risk Factors” and elsewhere in such filings\nand reports, including Geron’s annual report on Form 10-K for the year ended\nDecember 31, 2025, and subsequent filings and reports by Geron. Undue reliance\nshould not be placed on forward-looking statements, which speak only as of the\ndate they are made, and the facts and assumptions underlying the\nforward-looking statements may change. Except as required by law, Geron\ndisclaims any obligation to update these forward-looking statements to reflect\nfuture information, events, or circumstances.\n\nInvestors and Media\nDawn Schottlandt\nSenior Vice President, Investor Relations and Corporate Affairs\ndschottlandt@geron.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f39e4ea8-fa74-4b4c-b717-dfaaa0d8e390)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6wHhjH-20261012","title":"Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia","author":"Globe Newswire","ticker":"GERN","created":"2026-10-12T12:03:31.091Z","tickers":["GERN"],"exchange":"NASDAQ","article_body":"Presentations feature real-world experience and clinical evidence in\nlower-risk MDS, underscoring growing global scientific engagement with\nimetelstat \n\nFOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation\n(Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more\nmeaningful moments for people living with blood cancer, today announced two\noral presentations and one poster presentation highlighting imetelstat in\npatients with lower-risk myelodysplastic syndromes (LR-MDS) at the 88(th)\nAnnual Meeting of the Japanese Society of Hematology and the 2026 Annual\nMeeting of the German, Austrian and Swiss Societies for Hematology and Medical\nOncology. These presentations will feature real-world evidence and findings\nfrom the Phase 3 IMerge trial.\n\n“We’re encouraged by the growing interest in imetelstat across the global\nhematology community, supported by both the clinical evidence from IMerge and\nan expanding body of real-world evidence in lower-risk MDS,” said Joseph E.\nEid, M.D., Executive Vice President, Research and Development and Chief\nMedical Officer of Geron. “These presentations provide an important\nopportunity to share evidence relevant to patient populations across regions\nand engage with clinicians as we evaluate opportunities to bring\nimetelstat’s potential to more people living with LR-MDS around the\nworld.”\n\nKey takeaways from the presentations:\n\n88(th) Annual Meeting of the Japanese Society of Hematology 2026\n* Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic\nSyndromes: Insights From United States Claims Data (Eid, et al. Oral\n#O1-11C-4) * The retrospective study used closed medical and pharmacy claims\nwith linked enrollment and laboratory data from the Komodo Health database and\nincluded adults with MDS who initiated imetelstat between June 2024 and August\n2025, representing the first 14 months after the launch of imetelstat in the\nU.S.\n* In this real-world U.S. cohort (N=58), with a mean age of 75 years at\ndiagnosis, most patients (71%) initiated imetelstat in the third line or\nlater, with considerable anemia and a mean Charleson Comorbidity Index of 2.6\nat the time of initiation.\n* Despite substantial comorbidity burden, most patients remained on therapy\nthrough the early months when cytopenias typically emerge (~67% at 6 months;\nKaplan-Meier [KM] estimate).\n \n* Durable Clinical Outcomes With Imetelstat in Korean Patients With LR-MDS\n(Eid, et al. Poster #P3-12-5) * This post-hoc study explores characteristics\nof two Korean patients with LR-MDS who had over one year of red blood cell\ntransfusion independence (RBC-TI) with imetelstat, and explores the\nrelationship between cytopenias and treatment outcomes with imetelstat in 13\nKorean patients from the Phase 2/3 and heart rate-corrected QT interval (QTc)\nsubstudy of IMerge.\n* Both patients who achieved long-term response with imetelstat experienced\ngrade 3/4 neutropenia and grade 3/4 thrombocytopenia events early during\ntreatment; most resolved to grade ≤2 in <4 weeks, consistent with the\nbroader IMerge data.\n* Durable efficacy and manageable safety with imetelstat was exhibited in\nKorean patients across a range of patient and disease characteristics (sex, RS\nstatus, baseline erythropoietin [EPO], and baseline platelet levels).\n* In the 13 Korean patients, early cytopenias with imetelstat were associated\nwith better clinical outcomes, as previously reported in IMerge.\n2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology\nand Medical Oncology\n* Telomerase Inhibition With Imetelstat in Patients With Lower-Risk\nMyelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and\nClinical Outcomes (Brauer, et al. Oral #V755) * This presentation integrates\nkey evidence from the Phase 2/3 and QTc substudy of IMerge to support clinical\npractice, reporting on molecular changes, cytopenias and clinical outcomes\nwith imetelstat in LR-MDS, including emerging evidence suggesting treatment\nmay potentially alter the underlying biology of the disease.\n* Transient cytopenias observed early in treatment may be the result of an\non-target effect of imetelstat and may be predictive of a better therapeutic\nresponse.\n* Certain patients with LR-MDS and transfusion-dependent (TD) anemia who\nexperience sustained RBC-TI (≥8-week, ≥24-week, or ≥1-year) with\nimetelstat may experience improved health-related outcomes, including fatigue,\nQUALMS Total, QUALMS-P, and QUALMS-E scores.\nThe presentations are available on the “Publications & Presentations\n(https://www.globenewswire.com/Tracker?data=Lp8NcNEVJXMkQMAvpwFxQiHbltSpZTzTsv6hhG4M03qAmByzmI8FaMjJ53S9TqSS6y4z8bm9-KonRlfJYMJkIKEXQkq5_kBIwsb3kzjaD_MTF0exUYuTuHurO2MHWAt3-We0jYIse_Sl1fnYr_x2Fw==)”\npage of the Geron website.\n\nAbout RYTELO (imetelstat)\nRYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the\nU.S. for the treatment of adult patients with lower-risk myelodysplastic\nsyndromes (LR-MDS) with transfusion-dependent anemia requiring four or more\nred blood cell units over eight weeks who have not responded to or have lost\nresponse to or are ineligible for erythropoiesis-stimulating agents (ESAs). It\nis indicated to be administered as an intravenous infusion over two hours\nevery four weeks.\n\nIn addition, RYTELO is approved in the European Union as a monotherapy for the\ntreatment of adult patients with transfusion-dependent anemia due to very low,\nlow or intermediate risk myelodysplastic syndromes without an isolated\ndeletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory\nresponse to or are ineligible for erythropoietin-based therapy.\n\nRYTELO is a first-in-class treatment that works by inhibiting telomerase\nenzymatic activity. Telomeres are protective caps at the end of chromosomes\nthat naturally shorten each time a cell divides. In LR-MDS, abnormal bone\nmarrow cells often express the enzyme telomerase, which rebuilds those\ntelomeres, allowing for uncontrolled cell division. Developed and exclusively\nowned by Geron, RYTELO is the first and only telomerase inhibitor approved by\nthe U.S. Food and Drug Administration and the European Commission.\n\nPlease see RYTELO (imetelstat) full Prescribing Information, including\nMedication Guide, available at\nhttps://pi.geron.com/products/US/pi/rytelo_pi.pdf.\n\nAbout Geron\nGeron is a hematology-focused biopharmaceutical company pursuing more\nmeaningful moments for people living with blood cancer. Because patients\ncannot wait, we approach our work with urgency, bringing together deep\nexpertise in telomerase biology with patient perspectives and insights from\nclinical research and real-world care. Our medicine, RYTELO(®) (imetelstat),\nis approved in the United States and European Union for certain patients with\nlower-risk myelodysplastic syndromes (LR-MDS). We are building on our\nfoundation in telomerase inhibition by studying imetelstat in myelofibrosis,\nincluding a pivotal Phase 3 clinical trial in patients with JAK-inhibitor\nrelapsed/refractory disease, as well as other hematologic malignancies. Geron\nis a commercial-stage company with offices in Parsippany, New Jersey and\nFoster City, California. To learn more, visit www.geron.com or follow us on\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=TSGgR31HMBNF7dY52wvOkKAlQsiuBLX1wiNJ4nA94QhfTFtIjCVqKc-MIOcZjgqFh-2A8Cz-UWNlFl9QfDH52jhmh8s3S7RSkD8F_TmZtco=).\n\nUse of Forward-Looking Statements\n\nExcept for the historical information contained herein, this press release\ncontains forward-looking statements made pursuant to the “safe harbor”\nprovisions of the Private Securities Litigation Reform Act of 1995. These\nforward-looking statements include, without limitation, those regarding: (i)\nthe potential clinical significance of data presented from the IMerge trial\nand real-world evidence analyses; (ii) the potential relationship between\ntreatment-emergent cytopenias and clinical outcomes; (iii) the potential for\nimetelstat to affect the underlying biology of lower-risk MDS; (iv) Geron’s\nplans and efforts to expand awareness and understanding of imetelstat through\nscientific engagement; (v) Geron’s plans to pursue opportunities to bring\nimetelstat to patients outside the United States; (vi) the future development\nof imetelstat in lower-risk myelodysplastic syndromes, myelofibrosis and other\nhematologic malignancies; and (vii) other statements that are not historical\nfacts. These forward-looking statements involve risks and uncertainties that\ncan cause actual results to differ materially from those in such\nforward-looking statements. These risks and uncertainties, include, without\nlimitation, risks and uncertainties related to: (a) whether data analyses and\nobservations from clinical trials and real-world experience are predictive of\nfuture clinical outcomes; (b) whether imetelstat demonstrates\ndisease-modifying activity or other benefits in patients; (c) whether\ntreatment-emergent cytopenias are predictive of clinical outcomes or reflect\non-target biological activity; (d) whether future clinical trial results,\nanalyses and observations are consistent with prior findings; (e) whether\nregulatory authorities permit the continued development of imetelstat on a\ntimely basis, or at all; (f) whether Geron is successful in commercializing\nRYTELO outside of the United States; (g) whether there are failures or delays\nin manufacturing or supplying sufficient quantities of RYTELO or clinical\ntrial materials; and (h) risks and uncertainties relating to the development,\nregulatory review, and commercialization and market acceptance of imetelstat.\nAdditional information regarding these risks and uncertainties and additional\nrisks, uncertainties and factors that could cause actual results to differ\nmaterially from those in the forward-looking statements are contained in\nGeron’s filings and periodic reports filed with the Securities and Exchange\nCommission under the heading “Risk Factors” and elsewhere in such filings\nand reports, including Geron’s annual report on Form 10-K for the year ended\nDecember 31, 2025, and subsequent filings and reports by Geron. Undue reliance\nshould not be placed on forward-looking statements, which speak only as of the\ndate they are made, and the facts and assumptions underlying the\nforward-looking statements may change. Except as required by law, Geron\ndisclaims any obligation to update these forward-looking statements to reflect\nfuture information, events, or circumstances.\n\nInvestors and Media\nDawn Schottlandt\nSenior Vice President, Investor Relations and Corporate Affairs\ndschottlandt@geron.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f39e4ea8-fa74-4b4c-b717-dfaaa0d8e390)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-12T12:03:31.142021922Z","server_sent_at_ms":1791806611142},"received_at":"2026-10-12T12:03:31.192Z","source_url":null},"analysis":{"id":"154702","press_release_id":"166342","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Geron announced oral and poster presentations of imetelstat (RYTELO) data in lower-risk MDS at hematology congresses in Japan and the German-Austrian-Swiss region.\n\nThe data include a real-world U.S. claims cohort of 58 patients — most initiating in third line or later — showing ~67% remained on therapy at 6 months, plus durable transfusion independence in Korean patients from IMerge.\n\nPresentations also integrate IMerge molecular findings, suggesting early transient cytopenias may be an on-target effect predictive of better response. The release underscores growing global scientific engagement supporting international commercial expansion.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Global scientific engagement around RYTELO builds the real-world evidence case for international expansion, but no new pivotal data."},"keyFigures":{"drugName":"RYTELO (imetelstat)","phaseOfTrial":"Phase 3","customDimensions":{"korean_patients_n":13,"retention_6_months":"~67% (KM estimate)","real_world_cohort_n":58,"mean_age_at_diagnosis":75,"third_line_or_later_initiation":"71%"}},"quotedText":"We're encouraged by the growing interest in imetelstat across the global hematology community, supported by both the clinical evidence from IMerge and an expanding body of real-world evidence in lower-risk MDS","namedEntities":{"people":[{"name":"Joseph E. Eid, M.D.","role":"Executive Vice President, Research and Development and Chief Medical Officer"},{"name":"Dawn Schottlandt","role":"Senior Vice President, Investor Relations and Corporate Affairs"},{"name":"Brauer","role":"presentation author"}],"products":["RYTELO (imetelstat)"],"companies":[{"name":"Geron Corporation","ticker":"GERN","relationship":"filer"},{"name":"Komodo Health","relationship":"data provider"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Conference presentations of already-known Phase 3 IMerge data plus small real-world evidence cohorts (N=58 US, 13 Korean patients). Supportive commercial momentum but no new pivotal data, regulatory action, or revenue figures."},"tickerRelevance":{"others":[],"primary":"GERN"},"globalImportance":22,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"isNewData":false,"tickerTier":"mid-cap commercial biotech","eventGravity":"conference data presentations, no new pivotal results","retailFavoriteBoost":"moderate (biotech with active commercial launch)"}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Geron announced oral and poster presentations of imetelstat (RYTELO) data in lower-risk MDS at hematology congresses in Japan and the German-Austrian-Swiss region.\n\nThe data include a real-world U.S. claims cohort of 58 patients — most initiating in third line or later — showing ~67% remained on therapy at 6 months, plus durable transfusion independence in Korean patients from IMerge.\n\nPresentations also integrate IMerge molecular findings, suggesting early transient cytopenias may be an on-target effect predictive of better response. The release underscores growing global scientific engagement supporting international commercial expansion.","key_figures":{"drugName":"RYTELO (imetelstat)","phaseOfTrial":"Phase 3","customDimensions":{"korean_patients_n":13,"retention_6_months":"~67% (KM estimate)","real_world_cohort_n":58,"mean_age_at_diagnosis":75,"third_line_or_later_initiation":"71%"}},"named_entities":{"people":[{"name":"Joseph E. Eid, M.D.","role":"Executive Vice President, Research and Development and Chief Medical Officer"},{"name":"Dawn Schottlandt","role":"Senior Vice President, Investor Relations and Corporate Affairs"},{"name":"Brauer","role":"presentation author"}],"products":["RYTELO (imetelstat)"],"companies":[{"name":"Geron Corporation","ticker":"GERN","relationship":"filer"},{"name":"Komodo Health","relationship":"data provider"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T12:03:36.985Z","global_importance":22,"audience_relevance":30,"importance_components":{"isNewData":false,"tickerTier":"mid-cap commercial biotech","eventGravity":"conference data presentations, no new pivotal results","retailFavoriteBoost":"moderate (biotech with active commercial launch)"}},"durationMs":5769,"modelName":"glm-5.3-flashx"}}